EQL Pharma AB Provides Earnings Guidance for the Full Year 2019 and Provides Earnings Results for the Year 2020 and 2021
EQL Pharma AB (publ) provided earnings guidance for the full year 2019. The company estimate that sales for 2018/2019 will increase by more than 30% compared with the corresponding period last year.
The company continues to retain its target of growing at least 30% on average per annum over the 5- year period 2016 to 2020/2021, and aims at operating profit to grow at least the same rate as revenue growth. The assumed growth of 30% per annum will be distributed uneven over the five year period.